Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALY), Stat News reported citing a notice issued by the federal agency.
- The department has cited the lack of evidence of "a robust and meaningful clinical benefit" alongside safety concerns.
- Sales reps will not be allowed to promote the drug to VA doctors, either, another agency document shows.
- However, the VA unveiled that it would make exceptions for certain patients and announced requirements for the issuance of coverage, such as recent MRI brain scans, mild Alzheimer's, and prescriptions from providers who specialize in the treatment of dementia.
- The latest hit to the uptake of the drug comes after U.S. Medicare started a review process for national Medicare coverage of Biogen's Aduhelm.
- Price Action: BIIB shares closed at $339.05 on Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!